Mechanical Heart Valve Management

Core Objectives

The American College of Cardiology recommends that mechanical valves are designed to eliminate structural valve failure, which is the primary limitation of bioprosthetic valves 1, 2
Ball-and-cage prostheses have demonstrated excellent mechanical stability at follow-up intervals exceeding 30 years, providing a durable option for patients 1, 2
Modern bileaflet valves appear mechanically stable and are relatively hemodynamically efficient, making them a suitable choice for many patients 1, 2
The structural stability of mechanical valves translates to freedom from reoperation due to valve deterioration, unlike bioprosthetic valves where approximately 50% fail by 10 years in patients under 40 years of age 1

The American College of Cardiology recommends that all patients with mechanical valves require lifelong anticoagulation with a vitamin K antagonist (VKA) to prevent valve thrombosis and thromboembolic events 3
The thrombogenicity of mechanical valves stems from the intravascular prosthetic material and abnormal flow conditions, causing platelet activation, and VKA therapy reduces the incidence of valve thrombosis or embolism from 8.6 to 1.8 per 100 patient-years 3, 4
VKA therapy is protective against valve thrombosis (OR: 0.11) and thromboembolic events (OR: 0.21), highlighting its importance in mechanical valve management 3

The American Heart Association recommends an INR target of 2.5-3.5 for the first 3 months after mechanical aortic valve replacement, and 2.0-3.0 beyond 3 months 1, 2
For mechanical mitral valves, the INR target is 2.5-3.5 indefinitely, and low-dose aspirin (75-100 mg daily) should be added to warfarin for all mechanical valves 4, 1, 2

The annual bleeding risk with appropriate anticoagulation is 1-2%, and there is a persistent thromboembolism risk despite warfarin therapy, highlighting the need for careful management 1, 2
Prosthetic valve endocarditis and hemodynamic inefficiency in smaller valve sizes are potential risks associated with mechanical valves 1, 2
Although the goal of mechanical valve engineering has been to produce a valve that does not require anticoagulation with warfarin, this has not been achieved, and trials attempting to diminish or eliminate warfarin have demonstrated high rates of thromboembolism 1, 2, 6